CTNNB1 mutations and Wnt/β-catenin pathway activation are closely associated with the “immune exclusion class” that is characterized by immune exclusion and anti-immunotherapies in HCC (Figure 3) (78, 88, 89). This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.